We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Erasca Inc (ERAS) USD0.0001

Sell:$14.14 Buy:$14.25 Change: $1.04 (6.85%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $1.04 (6.85%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $1.04 (6.85%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Erasca, Inc is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company is engaged in oncology and RAS targeting to create therapies and combination regimens for the treatment of cancer. Its product candidates are ERAS-007 and ERAS-601, which together comprises its MAPKlamp. In addition, it also includes two discovery programs, ERAS-9 and ERAS-11, small molecule inhibitor programs targeting SOS1 and MYC, respectively. Its MAPKlamp is an approach targeting upstream and downstream nodes in the RAS/MAPK pathway designed to shut down, or clamp, the signaling of various oncogenic drivers, such as RTKs, NF1, RAS, RAF, and MEK alterations trapped in between any nodes involving this pathway. With its MAPKlamp approach, it induces tumor regression in RAS/MAPK pathway-driven cancers, while also blocking the escape routes that lead to tumor resistance.

Contact details

10835 Road To The Cure, Suite 140
United States
+1 (858) 4656511

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.72 billion
Shares in issue:
121.25 million
United States
US dollar

Key personnel

  • Jonathan Lim
    Chairman of the Board, Chief Executive Officer, Co-Founder
  • David Chacko
    Chief Financial Officer
  • Michael Varney
    Director, Chair of Research and Development
  • Brian Baker
    Senior Vice President - Finance
  • Nik Chetwyn
    Senior Vice President - Operations
  • Chandra Lovejoy
    Senior Vice President - Regulatory Affairs
  • David Luo
    Vice President - Clinical Research and Operations
  • Bao Truong
    Vice President and Program Team Leader
  • Minli Xie
    Vice President - Pharmaceutical Development and Operations
  • Dawei Xuan
    Vice President - Clinical Pharmacology

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.